Benzinga | Nov 5, 2021 09:44AM EDT

Benchmark Downgrades Regeneron Pharmaceuticals to Hold

Benchmark analyst Aydin Huseynov downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Buy to Hold.